Hepatitis C Newsletter
www.HepCChallenge.org
August 2011
Clinical
Trials, Cohort Studies, Pilot Studies
Insulin resistance is
independently associated with significant hepatic fibrosis in Asian chronic
hepatitis C genotype 2 or 3 patients. Patel K, Thompson AJ, Chuang WL, et al. J Gastroenterol Hepatol. 2011 Jul;26(7):1182-1188. doi:
10.1111/j.1440-1746.2011.06722.x.
http://www.ncbi.nlm.nih.gov/pubmed/21410752
A
multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. Lan CL, Guillygomarc'h A, Danielou H, et al. J Hepatol. 2011 Jul 11. [Epub ahead of print]
Maladies du Foie, F-35033 Rennes, France;
INSERM, UMR-991, F-35000, France.
http://www.ncbi.nlm.nih.gov/pubmed/21756854
Hyporesponsiveness to pegifnα2b plus ribavirin in patients with hepatitis C-related advanced
fibrosis. Prati GM, Aghemo A, Rumi MG, et al. J Hepatol. 2011 Jul 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21756847
A Randomized Controlled Trial of
an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C
Treatment. Evon DM, Simpson K, Kixmiller
S, et al. Am J Gastroenterol. 2011
Jul 19. doi:
10.1038/ajg.2011.219. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21769136
Improved
Responses to Pegylated Interferon alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. Sarrazin C, Schwendy S, Möller B, et al. Gastroenterology.
2011 Jul 21. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21784046
Association of laboratory
parameters with viral factors in patients with hepatitis C. Ijaz B, Ahmad W, Javed FT, et
al. Virol J. 2011 Jul 21;8(1):361. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21777434
Mallory-Denk
Bodies are Associated with Outcomes and Histologic
Features in Patients with Chronic Hepatitis C. Rakoski MO,
Brown MB, Fontana RJ, et al. Clin Gastroenterol
Hepatol. 2011 Jul 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21782771
IL28B but not ITPA polymorphism
is predictive of response to pegylated interferon, ribavirin, and telaprevir triple
therapy in patients with genotype 1 hepatitis C. Chayama K,
Hayes CN, Abe H, et al. J Infect Dis. 2011 Jul;204(1):84-93.
http://www.ncbi.nlm.nih.gov/pubmed/21628662
Basic
and Applied Science, Pre-Clinical Studies
Simple
assay based on restriction fragment length polymorphism associated with IL28B
in chronic hepatitis C patients. Nakamoto S, Kanda T, Imazeki
F, Wu S, Arai M, Fujiwara K, Yokosuka O. Scand J Gastroenterol.
2011 Jul;46(7-8):955-61.
http://www.ncbi.nlm.nih.gov/pubmed/21529139
Resistance
mutations define specific antiviral effects for inhibitors of the hepatitis C
virus p7 ion channel. Foster
TL, Verow M, Wozniak AL, et al. Hepatology.
2011 Jul;54(1):79-90. doi: 10.1002/hep.24371.
http://www.ncbi.nlm.nih.gov/pubmed/21520195
Serum
apolipoprotein C-III is independently associated with
chronic hepatitis C infection and advanced fibrosis. Rowell J, Thompson AJ, Guyton JR,
et al. Hepatol Int. 2011 Jul 7. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21735316
Mechanistic characterization of gs-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis c
virus ns5b polymerase.
Shih IH, Vliegen I, Peng B, et al. Antimicrob Agents Chemother. 2011 Jul 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21746939
Hepatitis
C virus (HCV) envelope glycoproteins E1 and E2
contain reduced cysteine residues essential for virus
entry. Fraser J,
Boo I, Poumbourios P, Drummer HE. J Biol Chem. 2011 Jul 15. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21768113
Activation
of unfolded protein response and autophagy during HCV
infection modulates innate immune response. Estrabaud E, De Muynck
S, Asselah T. J Hepatol. 2011 Jul 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21723841
Characterization
of Serum Proteins Associated with IL28B Genotype among Patients with Chronic
Hepatitis C. Cyr
DD, Lucas JE, Thompson JW, et al. PLoS One. 2011;6(7):e21854. Epub 2011 Jul 5.
http://www.ncbi.nlm.nih.gov/pubmed/21750736
The
prognostic value of changes in serum ferritin levels
during therapy for hepatitis C virus infection. Ackerman Z, Pappo
O, Ben-Dov IZ. J Med Virol. 2011 Jul;83(7):1262-8.
doi: 10.1002/jmv.22093.
http://www.ncbi.nlm.nih.gov/pubmed/21567428
Functional
impairment of dendritic cells in patients infected
with hepatitis C virus genotype 1 who failed peginterferon
plus ribavirin therapy. Liang CC, Liu CH, Lin YL, Liu CJ,
Chiang BL, Kao JH. J Med Virol.
2011 Jul;83(7):1212-20. doi: 10.1002/jmv.22096.
http://www.ncbi.nlm.nih.gov/pubmed/21567425
High Serum Levels of CXCL11 in
Mixed Cryoglobulinemia Are Associated with Increased
Circulating Levels of Interferon-{gamma} Antonelli A, Ferri C, Ferrari SM, et al. J Rheumatol.
2011 Jul 1. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21724697
HIV/HCV/HBV
Coinfection
Interference of replication
between hepatitis B and C viruses in patients infected with HIV.
Yang
RR, Gui X, Chen XY, Zhu Y. J
Med Virol. 2011 Jul;83(7):1159-64.
doi: 10.1002/jmv.22102.
http://www.ncbi.nlm.nih.gov/pubmed/21567419
Treatment of
acute hepatitis C infection in HIV-infected patients. Boesecke C, Rockstroh JK. Curr Opin HIV AIDS. 2011 Jul;6(4):278-84.
http://www.ncbi.nlm.nih.gov/pubmed/21519248
Influence of interferon-based
therapy on liver fibrosis progression in HIV/HCV coinfected
patients: A retrospective repeated liver biopsy analysis. Ingiliz P, Valantin MA, Petrosi P, et al. J Hepatol. 2011 Jul 19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21781946
IL28B Polymorphism Associated
with Spontaneous Clearance of Hepatitis C Infection in a Southern Brazilian HIV
Type 1 Population. Lunge VR, da Rocha DB, Béria JU, Tietzmann DC, Stein AT,
Simon D. AIDS Res Hum Retroviruses. 2011 Jul 26. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21790472
An overview
of Triple infection with Hepatitis B, C and D viruses. Riaz M, Idrees M, Kanwal H, Kabir F. Virol J. 2011 Jul 27;8(1):368. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21791115
Low-density lipoprotein receptor
genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C
virus-coinfected patients. Pineda JA, Caruz A, Di Lello
FA, et al. AIDS. 2011 Jul 17;25(11):1415-20.
http://www.ncbi.nlm.nih.gov/pubmed/21572301
Complementary
and Alternative Medicine
Vitamin-D: An innate antiviral
agent suppressing Hepatitis C virus in human hepatocytes.
Gal-Tanamy M, Bachmetov L, Ravid A, et al. Hepatology. 2011 Jul 25. doi:
10.1002/hep.24575. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21793032
Glycyrrhizin
as antiviral agent against Hepatitis C Virus. Ashfaq UA, Masoud MS, Nawaz Z, Riazuddin S. J Transl Med. 2011
Jul 18;9(1):112. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/21762538
Epidemiology,
Diagnostics, and Miscellaneous Works
An
IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic
Hepatitis C. O'Brien
TR, Everhart JE, Morgan TR, et al. PLoS One. 2011;6(7):e20904. Epub 2011 Jul 8.
http://www.ncbi.nlm.nih.gov/pubmed/21760886
Comparison of 9 blood tests and
transient elastography for liver fibrosis in chronic
hepatitis C: the ANRS HCEP-23 study. Zarski JP,
Sturm N, Guechot J, Paris A, et al. J Hepatol. 2011 Jul 19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21781944
Infections and the liver.
Eksteen B. Dig Dis. 2011;29(2):184-90. Epub 2011 Jul 5.
http://www.ncbi.nlm.nih.gov/pubmed/21734383
Racial differences in hepatitis C treatment
eligibility. Melia MT, Muir AJ, McCone J, et
al. Hepatology. 2011 Jul;54(1):70-78.
doi: 10.1002/hep.24358.
http://www.ncbi.nlm.nih.gov/pubmed/21488082
Acute
hepatitis C in Korea: different modes of infection, high rate of spontaneous
recovery, and low rate of seroconversion. Kim JY,
Won JE, Jeong SH, et al. J Med Virol.
2011 Jul;83(7):1195-202. doi: 10.1002/jmv.22100.
http://www.ncbi.nlm.nih.gov/pubmed/21567423
A systematic review of hepatitis C virus
epidemiology in Asia, Australia and Egypt.
Sievert W, Altraif
I, Razavi HA, et al. Liver Int. 2011 Jul;31 Suppl 2:61-80. doi: 10.1111/j.1478-3231.2011.02540.x.
http://www.ncbi.nlm.nih.gov/pubmed/21651703
A systematic review of hepatitis C virus
epidemiology in Europe, Canada and Israel.
Cornberg M, Razavi
HA, Alberti A, et al. Liver Int. 2011 Jul;31 Suppl 2:30-60. doi:
10.1111/j.1478-3231.2011.02539.x.
http://www.ncbi.nlm.nih.gov/pubmed/21651702
Trends and projections of hepatitis C virus
epidemiology in Latin America. Kershenobich D, Razavi
HA, Sánchez-Avila JF, et al. Liver Int. 2011 Jul;31 Suppl 2:18-29. doi:
10.1111/j.1478-3231.2011.02538.x.
http://www.ncbi.nlm.nih.gov/pubmed/21651701
A systematic review and meta-analysis of
interventions to prevent hepatitis C virus infection in people who inject
drugs. Hagan H, Pouget
ER, Des Jarlais DC. J Infect Dis. 2011 Jul;204(1):74-83.
http://www.ncbi.nlm.nih.gov/pubmed/21628661
Unmet
needs among people reported with hepatitis C, New York City. Bornschlegel K, Crotty
KJ, Sahl S, Balter S. J
Public Health Manag Pract.
2011 Jul-Aug;17(4):E9-17.
http://www.ncbi.nlm.nih.gov/pubmed/21617400
The
increasing mortality burden of liver disease among opioid
dependent people: Cohort study. Gibson
A, Randall D, Degenhardt L. Addiction. 2011 Jul 12. doi:
10.1111/j.1360-0443.2011.03575.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21749525
Gaps in the Achievement of Effectiveness of HCV
Treatment in National VA Practice.
Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag
H, Kramerer JR. J Hepatol. 2011 Jul 11.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21756855
Liver
Cancer
Liver
cancer and non-hodgkin lymphoma in hepatitis C
virus-infected patients: results from the danvir
cohort study. Omland LH, Jepsen
P, Krarup H, et al. Int J
Cancer. 2011 Jul 21. doi: 10.1002/ijc.26283. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21780099
Peginterferon Maintenance
Therapy in Patients with Advanced Hepatitis C to Prevent Hepatocellular
Carcinoma: The Plot Thickens. Aghemo A, Colombo M. J
Hepatol.
2011 Jul 20. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21782763